Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.
Onxeo S.A. has announced the appointment of Dr. Robert L. Coleman and Dr. Jacques Mallet as independent members of its Board of Directors. Dr. Coleman, Chief Scientific Officer of US Oncology Network, brings extensive oncology expertise, particularly in ovarian cancer research. Dr. Mallet, former SVP at Sanofi, offers over 30 years of experience in pharmaceutical R&D and corporate strategy. This strategic appointment aims to enhance Onxeo's clinical development, particularly for its innovative oncology drug AsiDNA™. The company's focus is on pioneering treatments targeting DNA Damage Response in oncology.
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO) has appointed Dr. Robert L. Coleman and Dr. Jacques Mallet as independent members of its Board of Directors. Dr. Coleman, a leading cancer specialist and Chief Scientific Officer at US Oncology Network, brings extensive experience in cancer treatment innovation. Dr. Mallet offers over 30 years in the pharmaceutical industry, notably in corporate strategy at Sanofi. Their expertise is expected to enhance Onxeo's development, particularly its pipeline focused on DNA Damage Response therapies, including the compound AsiDNA™.
Onxeo S.A., a clinical-stage biotechnology company, announced the appointment of Dr. Shefali Agarwal as the new Chairwoman of the Board of Directors on July 29, 2021. She succeeds Danièle Guyot-Caparros, who will continue as an independent board member and Audit Committee Chair. Dr. Agarwal brings extensive experience from her role as Chief Medical and Development Officer at Epizyme, Inc. Her expertise is expected to support Onxeo's ambitious clinical programs and growth, particularly in the U.S. market.